Head, Israeli Cytokines Standardization Laboratory
Head, Immunology Lab for Tumor Diagnosis
Head, Israeli Tumor Markers Reference Lab
The Sharett Institute of Oncology
Hadassah Medical Center
Jerusalem,. Israel 91120
Tel. 972-2-6776764 W
Fax: 972-2-6435308 W
Email: barakvivi@hadassah.org.il
Education and Experience
1970 - B.Sc. Biology, Hebrew University, Jerusalem, IsraeL
1975 - M.Sc. in Immunology & Basic Medical Sciences, with distinction, Hebrew University, Jerusalem, Israel.
1983 - Ph.D. in Immunology, Hebrew University, Jerusalem, Israel.
1985– Head, Immunology and Tumor Diagnosis Laboratory, Dept. of Oncology, Hadassah Medical Center, Jerusalem, Israel
1992- Lecturer in Oncology, Hebrew University, Jerusalem, Israel
2005– Associate Professor in Oncology, Hebrew University, Jerusalem, Israel.
Awards
1983 - World Health Organisation (WHO) Fellowship, American Association Immunology course.
1985 - Nahum Philosoph Award for Oncology Research.
1992 - First Prize Poster in Hadassah Research Day (together with Dr. Roisman).
1993 - First Prize Poster, 4th International Congress, Anti-Cancer Chemotherapy
1995 - Second IADR Prize of HATTON for dental research.
1996 - British Council and Barclay Family Cancer Res. Found. Award, Royal Free Hosp/Royal Marsden Hosp in London.
Editorial Board Member in International Journals
Tumor Biology, Tumor Marker Oncology , Biomarkers and Environment , In Vivo , European Cytokine Network , Biomedicine and Pharmacotherapy, Current Oncology.
Editor
Cytokine Receptors, by Humana Press
Board Member and Vice President of ISOBM
(Int. Society Oncology Biological Markers)
Board Member of EGTM
(European Group of Tumor Markers)
Scientific Advisory Board of IIAR- (International Institute for Anti Cancer Research)
Scientific Board of the European Committee for Research
Committees
§ Member of Early Detection of Cancer and Biomarkers - Israel Cancer Association
§ Scientific Committee of the Chief Scientist, Israeli Ministry of Health
§ Admitting Committee to Medical School, Hebrew University, Jerusalem
Appointments in Congresses
§ President, ISOBM Congress, 2005, Rhodes.
§ President, International Tumor Markers Congress,1997, Jerusalem.
§ Chairman ,Plenary Sessions: Molecular Oncology, Tumor Markers Utility, Cytokines as Tumor Markers.
§ Chairman, International Tumor Marker Congresses, 1994, 1995, 1996, 1997, 1998, 1999, 2001,2004
§ Chairman, Tumor Markers session, ISOBM 1993,1997,1998, 1999, 2000, 01,,03,,04,05,07,08,09
§ Chairman, Immunology and Genetics session, International Congress on Head and Neck Cancer, 1998.
§ Chairman, Cytokine session, Annual Israel Immunology Society 1992,1993, 1995, 1997, 1999
Membership
§ Member of European Cytokine Society.
§ Member of International Cytokine Society.
§ Member of American Association of Immunologists.
§ Member of European Academy of Allergology and Clinical Immunology.
§ Member of International Association for Breast Cancer Research.
§ Member of International Society for Oncology Biological Markers. (ISOBM)
§ Member of European Group Tumor Markers (EGTM)
§ Member of American Research Vision Organization (ARVO)
§ Member of International Association of Biological Standardization.
§ Member of International Society for Cancer Prevention and Detection.
§ Member of New York Academy of Sciences.
§ Member of Israeli Immunological Society.
§ Member of Israeli Society for Cancer Research.
RESEARCH PROJECTS:
A. THE ROLE OF CYTOKINES IN HEALTH AND DISEASE
1. Characterization of the M20 IL-1 Inhibitor - a new cytokine molecule
2. Involvement of cytokines/receptors in pathophysiology of Lymphomas /Leukemias
3. Evaluation of clinical potential of cytokines as markers for Leukemias / Lymphomas
4. Cytokines as biological markers in Autoimmune Diseases
5. Cytokines as biological markers in various diseases
B. THE ROLE OF TUMOR MARKERS FOR DIAGNOSIS, PROGNOSIS AND EVALUATION OF THERAPY RESPONSE
§ Prostate cancer markers - PSA, PAP, TPS
§ Breast cancer markers - CA15-3, CA27-29, MCA, TPS, Cerb-B2/ HER 2
§ Ovary cancer markers - CA125, CASA, TPS, HE-4, KALIKREINS
§ Gastro cancer markers - CEA, CA 19-9, CA 72-4
§ Lung cancer markers - CEA, Cyfra 21-1, TPS, NSE, SCC, Mesothelin, ProGRP
§ Bladder cancer markers - CEA, Cyfra 21-1, TPS
§ Melanoma, Skin and Uveal - S100, MIA, OPN, TPS
§ Hematological Cancers - TK, B2M,sIL-2R, IL-6
TEACHING at the HEBREW UNIVERSITY
Supervision of :
PhD and M.Sc. Degree Students
M.D Degree Students (Research Theme), M.D. Research Theme (6 months)
1. Hebrew University Medical School
Biology for Medical Students
2. Hebrew University Medical School/ Oncology Dept.
Lectures for Medical Students, (Fifth and Sixth Year)
3. Tel Aviv University Medical Schoolm
Lectures for continuing studies in medicine,
4. Hebrew University Medical School
Workshops - Immunology for Biology students
Lectures - Immunology for Medicine students
5. Hebrew University Medical School, Institute of Post-Graduate Medical Education
Lectures for community and Hadassah doctors
Lectures for Hadassah Oncology nurses Lectures for laboratory staff
Lectures for pharmacysts
6. Kupat Holim
Lectures for community doctors
Lectures for oncology pharmacologists
7. Hebrew University Medical School- School of Pharmacy
Lectures in Immunopharmacology
Course organizer + Prof. Levy – Sheafer
8. Hebrew University Medical School, School of Nursing
Lectures in Oncology
9. Haifa University Medical School
Lectures for Continuing studies in Medicine
10. Hebrew University Medical School:
Course organizer Biomarkers for health and disease
Selected Publications (since 1995):
Meirovitz, A, Kuten, M, Billan, S, Abdah-Bortnyak, R, Sharon, A, Peretz, T, Sela, M, Schaffer, M, and Barak, V. Can cytokines predict the severity of acute mucositis and the need for PEG during chemo-radiation treatment to Head and Neck Cancer? A prospective pilot study.
Radiation Oncology, 5: 16-20, 2010
I.Arad , B Bar-Oz, Z Ergaz, A Nir, and V Barak. Lack of correlation between Interleukin–6 and N-Terminal Pro-brain Natriuretic Peptide cord blood levels in premature infants. In Press, IMAJ, 2010
Goldschmidt N , Werber A, Neuman T , Kalickman I , Barak V . VEGF as a major parameter for diagnosis and follow up of a patient with POEMS syndrome. In Press, J Neurological Sciences, 2010
Oberbaum M., Spira R., Lukasiewicz E., Armon Y., Samuels N., Singer R., Barak V., Izbicki G., Einav S.., Hersch. M. In Press, Alternative Therapies in health and medicine, 2010
Barak V. Schlesinger, Blank M, Agmon-Levin N. KalickmanI, Selmi C. Gershwin M.E. and Shoenfeld Y. . Serum inflammatory Cytokines, Complement components, and soluble Interleukin 2 Receptor in Primary Biliary Cirrhosis. Journal of Autoimmunity, 33:178- 182, 2009
G Gutman, V Barak , S Maslovitz, A Amit, J. Lessing, E Geva Recombinant luteinizing hormone (rLH) induces ovarian follicular Adiponectin over expression in vivo: implications for enhanced insulin sensitivity.
Fertility and Sterility, 91:5:1837-1841, 2009
J. H.Waknine-Grinberg ,J. El-On , V. Barak, Y. Barenholz, J. Golenser. The Immuno modulatory Effect of Sambucol on Leishmanial and Malarial Infections Planta Med, 75: 581–586, 2009;
B. Nisman, V Yutkin, T. Peretz, A Shapiro, V. Barak, D Pode. The follow up of patients with non muscle invasive Bladder Cancer by urine cytology, abdominal US and urine CYFRA 21-1: a pilot study.
AntiCancer Research, 29:4281-4286, 2009
R. Dror , M. Lederman, K. Umezawa, V. Barak, J. Pe’er, I. Chowers. Characterizing the Involvement of the Nuclear Factor-kappa B (NFkB) Transcription Factor in Uveal Melanoma. In Press, IOVS, 2009
V Barak , I Kaiserman, S Frenkel , K Hendler , I Kalickman, J Pe’er. The Dynamics of Serum Biomarkers and Their Role in Predicting Metastatic Uveal Melanoma. In Press, AntiCancer Research, 2009
Hendler K, Frenkel S, Baruch R, Kalickman I, Kaiserman I, Barak V, Pe'er J. The dynamics of Liver Function Tests in the Early Diagnosis of Metastases from Uveal Melanoma. In Press, AntiCancer Research, 2009
B. Nisman, H. Biran, N. Ramu, N. Heching, V. Barak, T. Peretz. The diagnostic and prognostic value of ProGRP in Lung Cancer. In Press, AntiCancer Research, 2009
Nisman B, ,Biran H, Heching N, Barak V, Nemirovsky I, Peretz T: Prognostic role of serum CK19 in advanced NSCLC association of marker changes after two chemotherapy cycles with different measures of clinical response and survival. British J. of Cancer 98(1):77-79, 2008
Gutman G, Barak V, Maslovitz S, Amit A, Lessing J, Geva E,: Regulation of VEGF-A and its soluble -R sFlt-1 by luteinizing Hormone- in vivo implication for ovarian follicle angiogenesis. Fertility and Sterility, 89(4) 922-926, 2008
Barak V, Frenkel S, Kalickman I, Maniotis A, Folberg R and Pe'er J: Serum markers to detect Metastatic Uveal Melanoma. Anti Cancer Research, 27:1897 - 1900, 2007
Orbach H, Zandman-Goddard G, Amital H, Barak V, Szekanecz Z, Szucs G, Danko K, Nagy E, Csepany T, Carvalho JF, Doria A, Shoenfeld Y: Novel biomarkers in Autoimmune Diseases: prolactin, ferritin, Vitamin D, and TPA.
Ann N Y Acad Sci , 1109:385-400, 2007
Beloseski Y, Hendel D, Weiss A, Hershlivitz A, Grinblat Y, Pirotsky A, Barak V.: Cytokines and CRP production in Hip-Fracture-operated elderly patients. J-Gerontol-A-Biol-Sci-Med-Sci ,62(4),420-426, 2007
Kadkol S, Lin A, Barak V, Valyi-Nagy K, Majumdar D, Setty S, Maniotis A, Folberg R and Pe'er J: Modeling the behavior of Uveal Melanoma in the liver. IOVS, 48(7),2967-74, 2007
Portugal M, Barak V, Ginsburg I, Kohen R,: Interplay among oxidants, antioxidants, and cytokines in skin disorders: Present Status and future considerations. Biomed Pharmaco Therapy,61(7);412-492, 2007
Amital H, Barak V, Winkler R, Rubinow A,: Impact of treatment with Infliximab on serum cytokine profile of patients with Rheumatoid and Psoriatic Arthritis (RA). Ann. N.Y. Acad. Sci. 1110: 649 -660, 2007
Barak V, Frenkel S, Valyi-Nagy K, Leach L, Apushkin MA, Lin A, Kalickman I, Baumann NA, Pe'er J, Maniotis A, Folberg R,: Using the direct injection model of early Uveal Melanoma hepatic metastases to identify TPS as a potentially useful serum biomarker . IOVS, 48 (10),4399 -402, 2007
Nisman B, Heshing N, Biran H, Barak V and Peretz TThe prognostic significance of pretreatment circulating neuroendocrine markers chromogranin A and Pro-Gastrin releasing peptide in patients with advanced NSCLC.
Tumor Biology. 27: 8-16, 2006
Kadkol S, Lin A, Barak V, Kalickman I,Leach L, Valyi-Nagy K, Majumdar D, Setty S, Maniotis A, Folberg R and Pe'er J Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study IOVS. 47(3): 802-806,2006
Reichert F, Barak V, Tarshis M, Prindull G, Tarshis E, a Ben-Ishay Z : Anti-angiogenic effects and regression of localized murine AML produced by anti-VEGF and anti-Flk1 antibodies. Eur J Hematol. 75: 41-46, 2005.
Vaisman N., Zaruk Y., Shirazi I., Kaysar N., Barak V: The effect of fish oil supplementation on cytokine production in children. Eur. Cytokine Netw. 16(3): 194-198, 2005.
Molina R, Barak V, van Dalen A, Duffy M, Einarsson R, Gion M, Goike H, Lamerz R, Nap M, Soletormos G, Stieber P: Tumor Markers in Breast Cancer - Recommendations. European Group of Tumor Markers (EGTM). Tumor Biology. 26: 281-293, 2005.
Abramov Y, Ezra Y, Elchalal U, Ben-Shahar I, Fasouliotis S, Barak V: Production of peritoneal fluid rich in IL-6 and sIL-2R in obstructed labor. Acta Obstet. Gynecol. Scan. 83:358-363, 2004.
Raveh D, Shemesh O, Ashkenazi Y, Winkler R and Barak V: Infliximab, a TNFa blocking agent, as a treatment for Nephrotic Syndrome. Pediatric Nephrology. 19: 1281-1284, 2004.
Barak V, Elchalal U, Edelshtein M, Abramov Y: IL-18 correlates with capillary hyperpermeability in OHSS.
Fertility and Sterility. 82(2): 415-420, 2004.
Vaisman N, Karov Y, Hahn T, Silger E, Barak Y, Barak V: Impaired hematopoiesis in patients with anorexia nervosa: The effect of refeeding. Cytokine, 26: 255-261, 2004.
Barak V, Kalichman I, Birkenfeld S and Ginzburg I: Effect of Padma 28 on Cytokine production. Eur Cytokine Net. 15(3): 203-209, 2004.
Barak V, Goike H, Panaretakis K and Einarsson R : Clinical utility of Cytokeratins as tumor markers J Clin Biochem. 5: 529-540, 2004.
Nisman B, Barak V, Hubert A, Kaduri L, Lyass O, Baras M, Peretz T: Prognostic factors for survival in metastatic breast cancer during first-line paclitaxel chemotherapy. Anticancer Research 23:1939-1942, 2003.
Muayad AZ, Barak V, Traub L, Moroz H: PLIF induces IL-10 production in monocytes: a calmodulin-p38 mitogen-activated protein kinase-dependent pathway. The FASEB J 10: 1096, 2003.
Vaisman N, Leibovitz E, Dagan R, Barak V: The involvement of IL-6 and IL-8 in acute invasive gastroenteritis of children. Cytokine, 22(6):194 -198, 2003.
Shapira J, Berenstein J, Engelhardt D, Cahan S, Kalickman I, Barak V:( Correlation between cytokine levels in gingival crevicular fluid of erupting primary teeth and systemic disturbances accompanying teething. Pediatric Dentistry, 25(5):441- 448, 2003.
Abramov D, Erez E, Tamariz M, Dagan O, Pearl E, Abramov Y, Gendel B, Desai N, Katz J, Vidne B and Barak V.: Plasma Vascular Endothelial Growth Factor (VEGF) is a predictor of the severity of postoperative capillary leak syndrome in neonates undergoing cardiopulmonary bypass. Pediatric Surg. Int. 18: 54-59, 2002.
Abramov Y., Anteby S.O., Fasouliotis S.J. and Barak V., The role of inflammatory cytokines in Meig's syndrome.
Obstet and Gynecol., 99:917-919, 2002.
Gavish Z., Pinthus J., Barak V., Ramon J., Nagler A., Eshhar Z., Pines M. Growth inhibition of prostate cancer xenografts by Halofuginone. The Prostate, 51: 73-83, 2002.
Nisman, B., Barak, V., Shapiro, A., Golijanin, D., Peretz, T., Pode, D. Evaluation of UrineCYFRA 21-1 for the Detection of Primary and Recurrent Bladder Cancer. Cancer. 94:2914-2922, 2002.
Barak,V., Halperin, T. Birkenfeld, S. and Kalickman, I. The effects of Herbal remedies on the production of human inflammatory cytokines and anti - inflammatory cytokine IMAJ, 4:1-4, 2002.
Scheinowitz M, Heled Y, Chouraqui P, Vered Z, Hayardeni Y, Kotlyar A, Castel D, Livschitz S, Barak V, Savion N, Eldar M: Dalteparin sodium (Fragmin) administration following acute infarction does not affect myocardial perfusion and function in swine. Cardiovascular drugs therapy, 16(4), 303-309, 2002.
Barak V, Nisman B, Hubert A, Lyass O, Peretz T: Cytokeratins - Clinical utility in breast cancer. Journal of clinical ligand assay, 35(1): 40-42, 2002.
Weiss L, Barak V, Zeira M, Gross D, Abdul-Hai A, Raibstein I, Reich S, Hirschfeld E, Gross D, Slavin S: Cytokine production in Linomide - treated NOD mice and the potential role of TH1/TH2 shift on autoimmune and anti - inflammatory processes. Cytokine, 19(2):85-93, 2002.
Nisman, B., Barak, V., Shapiro, A., Golijanin, D., Peretz, T., Pode, D. Evaluation of Urine CYFRA 21-1 for the Detection of Primary and Recurrent Bladder Cancer. Cancer. 94,2914-2922, 2002
Barak V., Nisman B., Hubert A., Lyass O., Peretz T Cytokeratins - Clinical utility in breast cancer. Journal of clinical ligand assay, 35(1): 40-42, 2002
Ben-Ishay Z and Barak V. Possible cause of Bone Marrow stromal damage in mice administered cytosine arabinoside. Eur. J. Haematology, 66:230-237, 2001.
R. Einarsson and Barak V. TPS: A Cytokeratin serum Tumor Marker for effective therapy control of cancer patients with focus on breast cancer. J. Clinical Ligand Assay. 22(4), 348-352, 2000.
Barak V. Cytokeratins as tumor markers. J. Tumor Marker Oncology. 15(3), 3-4, 2000.
Nisman B., Heching N. and Barak V. Serum tumor markers in resectable and non-resectable non-small cell lung cancer. J. Tumor Marker Oncology. 15(3), 11-23, 2000.
Barak V., Nisman B., Hubert A., Lyass O., Kaduri L., Peretz T. Prognostic efficacy of TPS in breast cancer. J. Tumor Marker Oncology. 15(3), 4-10, 2000.
Nisman, B., Amir, G., Lafair, J., Heshing, J., Liass, O., Peretz, T.and Barak, V.,: Prognostic value of TPS, Cyfra 21-1 and CEA in different histologic types of non-small cell lung cancer. Anticancer Research.19(5):3549-3552, 1999.
Barak, V., Nisman, B., Polliack, A: TNF family in hairy cell leukemia - correlation to disease activity and prognosis. Eur. J. of Hematol. 62:71-75, 1999.
Barak., V., Nisman, B., Kalichman, I., Farbstein, H, Baider, L., Stephanos, S., Kaplan, A. and Peretz, T. Changes in cytokine production of breast cancer patients treated with Interferons. Cytokine. 10(12) 977-983, 1998.
Nagler, A., Bishara, A., Brautbar, C., and Barak, V.: Dysregulation of inflammatory cytokines in unrelated bone marrow transplantation. Cytokines, Cellular and Molecular Therapy. 4:161-167, 1998.
Nisman, B., Lafair, J., Heshing, J., Lyass, O., Peretz, T. and Barak, V.,: Evaluation of TPS, Cyfra 21-1 and CEA in non-small cell lung cancer: does the combined use of cytokeratin markers give any additional information? Cancer. 82:1850-1859, 1998.
Barak, V., Nisman, B., Polliack, A., Vannier, E., and Dinarello, C.A.: Circulating levels of IL-1 family members in Hairy Cell Leukemia: correlation with disease activity and response to treatment. Eur. Cytokine Netw. 9(1):33-39, 1998.
Van Dalen, A., Barak, V., Cremaschi, A., Gion, M., Molina, R., Namer, M., Stieber, P., Sturgeon, C., Einarsson, R. The prognostic significance of increasing marker levels in metastatic breast cancer patients with clinically complete remission, partial remission or stable disease. The Int. J. Biol. Markers. 13(1):10-15, 1998.
Nisman, B., Barak, V., Heching, N., Kramer, M., Reinus, C., Lafair,J. Cytokeratin markers in Malignant Pleural Mesothelioma. Cancer Det. Prevent. 22(5):416-422, 1998.
Nisman, B., Lafair, J., Lyass, O., Dranitzki-Elhalel, M. and Barak, V.: Serum Levels of CEA, SCC, TPS and CYFRA 21-1 in Hemodialysis Patients. J. Tumor Marker Oncology. 13(2):33-40, 1998.
Barak, V., Schwartz, A., Kalickman, I., Nisman, B., Gurman, G., Shoenfeld, Y: Hypophosphatemia as a diagnostic tool in sepsis: the role of cytokines. Am. J. of Medicine. 104:40-47, 1998.
Barak, V., Nisman, B.,Roisman, I.,Hubert, A.,Farbstein, H.,Baider, L.,Kaplan, A., Halperin, T., Stephanos, S.Peretz, T.: TPS in assessing response to therapy and prognosis of breast cancer patients treated with interferons. J. Tumor Marker Oncology. 12(4):17-26, 1997.
Peretz, T., Kaplan Denour, A., Baider, L., Hubert, A., Stephanos, S. and Barak,V.: The combination of Interferon and Tamoxifen for patients with advanced breast cancer and negative estrogen receptors. The Breast. 6(4):190-193, 1997.
Van Dalen, A., Heering, K.J. (Gouda), Barak, V., Peretz, T.(Jerusalem), Cremaschi, A., Geroni, P. (Romano di Lombardia), Gion, M., Saracchini, S. (Venice), Molina, R. Barcelona), Namer, N. (Nice), Stieber, P.(Munich), Sturgeon, C., Leonard, R.C.F. (Edinburgh), Einarsson, R. (Stockholm): Treatment response in metastatic breast cancer: a multicenter study comparing UICC criteria and tumor marker changes. The Breast. 5:82-88, 1996.
Barak, V, , Livni, N., Peretz, T., Libson, Y., Manny, J., Durst, A.L.and Roisman, I.: The role of CA 15-3 expression in serum and tissue of breast cancer patients. J. Tumor. Marker Oncology. 10(3):39-45, 1995.
REVIEWS, EDITORIALS
1. Roisman I, Gimon Z and Barak V, (1989): Male breast cancer. Harefuah. ll7: 68-74, (Hebrew,)
2. Roisman I, Gimon Z and Barak V. (1989):. Breast cancer and pregnancy. Harefuah. ll7: 44l-445, (Hebrew,)
3. Roisman I, Gimmon Z, Barak V and Manny J (1991): Clinical applicability of intraperitoneal administration of nutrients and drugs. Harefuah. l20: 76-80, (Hebrew,
4. Roisman I, Barak V, Gimon Z and Durst A (1991): Appropriate Diagnostic Steps for Proper Clinical Evaluation of Breast Lesions in the Community. Harefuah. 120: 266-270, (Hebrew,)
5. Barak V and Roisman I (1995): Urogenital tumor markers. BAMAH. 8: 5-11, (Hebrew)
6. Barak V (1995): Editorial: Cytokines and cytokine receptors in Behcet's disease. Isr. J. Med. Sci. 31: 374-375
7. Barak V:(PI) (1995): Cytokine receptors in disease. Isr. J. Med. Sci. 31: 1-9,
8. Barak V (2000): Cytokeratins as Tumor Markers. J. Tumor Marker Oncology. 15(3), 3-4
CASE REPORTS
1. Roisman I, Barak V, Okon E, Sherman Y, Libson E, Durst AL (1991): Adenolipoma of breast. The Breast . 4: 153-159
2. Roisman I, Barak V, Manny J, Libson E, Wygoda M, Durst AL (1991): Fat necrosis below musculo-cutaneous flap mimicking carcinoma of breast. Annals of Plastic Surgery. 26: 479-482
3. Roisman I, Barak V, Okon E, Manny J and Durst AL (1991): Benign cystosarcoma phylloides of breast in an adolescent female. The Breast . 4: 299-305
4. Putterman C, Barak V, Caraco Y and Shalit M (1993): Episodic angioedema with eosinophilia: association with T cell activation and cytokine production. Annals of Allergy. 70: 243-248
5. Shapira L, Smidt A, Van Dyke TE, Barak V, Soskolne AW, Brautbar C, Sela MN, Bimstein I (1994): Sequential manifestation of different forms of early onset periodontitis: a case report. J. of Periodontology. 65: 631-635
6. Abramov Y, Galun E, Granat M, Barak V, Abramov D, Plotkin V, Samueloff A (1995): Postpartum Systemic Capillary Leak Syndrome: A Possible Etiology. Acta. Obstet. Gynecol. Scand. 74: 395-398
7. Hirshberg B, Kramer M, Lotem M, Barak V, Shustin L, Amir G, Ben-Yehuda D and Ben-Yehuda A (1999): Chronic eosinophillic pneumonia associated with cutaneous T-cell lymphoma. Am. J. of Haematol. 60: 143-147
LETTERS TO THE EDITOR
1. Polliack A, Barak V, Dann EJ (1994): Rapid massive splenic relapse of Hairy Cell Leukemia during bone marrow remission after 2-CDA therapy: the spleen as a sanctuary in HCL? Blood 84(6): 2057-2058
2. Geva E, Gottesman G, Lerner-Geva L, Lang R, Pomeranz M, Barak V, Wolach, B (1995): Secondary amenorrea due to persistent corpus luteum in brucellosis. Does it involve inflammation-mediated cytokines? The Lancet 345(8943); 201-203
MULTI CENTER STUDIES
Van Dalen A, Heering KJ (Gouda), Barak V, Peretz T (Jerusalem), Cremaschi A, Geroni P (Romano di Lombardia), Gion M, Saracchini S (Venice), Molina R (Barcelona), Namer N (Nice), Stieber P (Munich), Sturgeon C Leonard RCF (Edinburgh), Einarsson R (Stockholm) (1996): Treatment response in metastatic breast cancer: a multi-center study comparing UICC criteria and tumor marker changes. The Breast. 5:82-88
Barak V, Kaiserman I, Frenkel S, Hendler K, Kalickman I, Folberg R S, J. Pe'er, The dynamics of serum Biomarkers and their role in predicting Metastatic Uveal Melanoma ANTI CANCER RESEARCH, IN Press, 2009
Patent
M20 Interleukin-1 Inhibitor
U.S. Patent appl. No. 07/354,330 filed May 19, 1989 by Vivian Barak and Abraham J. Treves and assigned to Hadassah Medical Organization.
|